To include your compound in the COVID-19 Resource Center, submit it here.

FDA biosimilars policies will bring interchangeable insulin to market

New FDA policies will lead to approvals of interchangeable insulin products that can be automatically substituted for branded insulin, FDA Commissioner Scott Gottlieb said Tuesday.

Gottlieb made the prediction in a statement about new guidance documents that outline how FDA will implement a law requiring that it stop regulating certain biologics, such as insulin and

Read the full 543 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers